These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

535 related articles for article (PubMed ID: 23835762)

  • 1. Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer.
    Lawrie TA; Bryant A; Cameron A; Gray E; Morrison J
    Cochrane Database Syst Rev; 2013 Jul; 2013(7):CD006910. PubMed ID: 23835762
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pegylated liposomal doxorubicin for first-line treatment of epithelial ovarian cancer.
    Lawrie TA; Rabbie R; Thoma C; Morrison J
    Cochrane Database Syst Rev; 2013 Oct; 2013(10):CD010482. PubMed ID: 24142521
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer.
    Newhouse R; Nelissen E; El-Shakankery KH; Rogozińska E; Bain E; Veiga S; Morrison J
    Cochrane Database Syst Rev; 2023 Jul; 7(7):CD006910. PubMed ID: 37407274
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Luteinising hormone releasing hormone (LHRH) agonists for the treatment of relapsed epithelial ovarian cancer.
    Wuntakal R; Seshadri S; Montes A; Lane G
    Cochrane Database Syst Rev; 2016 Jun; 2016(6):CD011322. PubMed ID: 27356090
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact of Pegylated liposomal doxorubicin in recurrent ovarian cancer: an updated meta-analysis of randomized clinical trials.
    Li XR; Zhu Y; Zhang GN; Huang JM; Pei LX
    J Ovarian Res; 2021 Mar; 14(1):42. PubMed ID: 33750444
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Taxane monotherapy regimens for the treatment of recurrent epithelial ovarian cancer.
    Patel A; Kalachand R; Busschots S; Doherty B; Kapros E; Lawlor D; Hall N; Stordal BK
    Cochrane Database Syst Rev; 2022 Jul; 7(7):CD008766. PubMed ID: 35866378
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Angiogenesis inhibitors for the treatment of epithelial ovarian cancer.
    Gaitskell K; Rogozińska E; Platt S; Chen Y; Abd El Aziz M; Tattersall A; Morrison J
    Cochrane Database Syst Rev; 2023 Apr; 4(4):CD007930. PubMed ID: 37185961
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer.
    Tattersall A; Ryan N; Wiggans AJ; Rogozińska E; Morrison J
    Cochrane Database Syst Rev; 2022 Feb; 2(2):CD007929. PubMed ID: 35170751
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized, open-label, phase III study comparing patupilone (EPO906) with pegylated liposomal doxorubicin in platinum-refractory or -resistant patients with recurrent epithelial ovarian, primary fallopian tube, or primary peritoneal cancer.
    Colombo N; Kutarska E; Dimopoulos M; Bae DS; Rzepka-Gorska I; Bidzinski M; Scambia G; Engelholm SA; Joly F; Weber D; El-Hashimy M; Li J; Souami F; Wing P; Engelholm S; Bamias A; Schwartz P
    J Clin Oncol; 2012 Nov; 30(31):3841-7. PubMed ID: 22987083
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent or refractory ovarian cancer: a systematic review and economic evaluation.
    Edwards SJ; Barton S; Thurgar E; Trevor N
    Health Technol Assess; 2015 Jan; 19(7):1-480. PubMed ID: 25626481
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation.
    Main C; Bojke L; Griffin S; Norman G; Barbieri M; Mather L; Stark D; Palmer S; Riemsma R
    Health Technol Assess; 2006 Mar; 10(9):1-132. iii-iv. PubMed ID: 16545208
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epidermal growth factor receptor blockers for the treatment of ovarian cancer.
    Morrison J; Thoma C; Goodall RJ; Lyons TJ; Gaitskell K; Wiggans AJ; Bryant A
    Cochrane Database Syst Rev; 2018 Oct; 10(10):CD007927. PubMed ID: 30321910
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expert consensus: Profiling and management of advanced or metastatic epithelial ovarian cancer.
    Pierre ME; Manneh R; Hernández A; Rodríguez J; Fletcher AV; Ramírez HM; Niño OM; Gómez DA; Sanabria D; Contreras F; Pieschacón JR; Calderón PH
    Rev Colomb Obstet Ginecol; 2024 Jun; 75(1):. PubMed ID: 39013199
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tolerability, efficacy, and safety of pegylated liposomal Doxorubicin in combination with Carboplatin versus gemcitabine-Carboplatin for the treatment of platinum-sensitive recurrent ovarian cancer: a systematic review.
    Holloway RW; Grendys EC; Lefebvre P; Vekeman F; McMeekin S
    Oncologist; 2010; 15(10):1073-82. PubMed ID: 20930103
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trabectedin plus pegylated liposomal doxorubicin (PLD) versus PLD in recurrent ovarian cancer: overall survival analysis.
    Monk BJ; Herzog TJ; Kaye SB; Krasner CN; Vermorken JB; Muggia FM; Pujade-Lauraine E; Park YC; Parekh TV; Poveda AM
    Eur J Cancer; 2012 Oct; 48(15):2361-8. PubMed ID: 22541893
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Retrospective study comparing irinotecan and pegylated liposomal doxorubicin in treatment of recurrent platinum-refractory/resistant epithelial ovarian cancer.
    Nomura H; Tsuda H; Kataoka F; Chiyoda T; Yamagami W; Tominaga E; Susumu N; Aoki D
    Eur J Gynaecol Oncol; 2012; 33(1):86-9. PubMed ID: 22439412
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of BRCA1 and XPG mutations on treatment response to trabectedin and pegylated liposomal doxorubicin in patients with advanced ovarian cancer: exploratory analysis of the phase 3 OVA-301 study.
    Monk BJ; Ghatage P; Parekh T; Henitz E; Knoblauch R; Matos-Pita AS; Nieto A; Park YC; Cheng PS; Li W; Favis R; Ricci D; Poveda A
    Ann Oncol; 2015 May; 26(5):914-920. PubMed ID: 25722380
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Retrospective comparative study of irinotecan and pegylated liposomal doxorubicin for platinum-resistant or -refractory epithelial ovarian and primary peritoneal carcinoma.
    Ichikawa R; Torii Y; Oe S; Kawamura K; Kato R; Hasegawa K; Udagawa Y
    Arch Gynecol Obstet; 2014 Nov; 290(5):979-84. PubMed ID: 24798935
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase 1b safety study of farletuzumab, carboplatin and pegylated liposomal doxorubicin in patients with platinum-sensitive epithelial ovarian cancer.
    Kim KH; Jelovac D; Armstrong DK; Schwartz B; Weil SC; Schweizer C; Alvarez RD
    Gynecol Oncol; 2016 Feb; 140(2):210-4. PubMed ID: 26644263
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.